Day One Biopharm Files 8-K on Shareholder Vote
Ticker: DAWN · Form: 8-K · Filed: May 24, 2024 · CIK: 1845337
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Day One Biopharm held a shareholder vote on May 23rd, details to follow.
AI Summary
Day One Biopharmaceuticals, Inc. filed an 8-K on May 24, 2024, reporting on a matter submitted to a vote of its security holders on May 23, 2024. The filing does not disclose the specific outcome or details of the vote.
Why It Matters
This filing indicates a significant corporate action or decision was put to a shareholder vote, the outcome of which could impact the company's future direction or governance.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain new financial or operational information that would immediately impact the stock price.
Key Players & Entities
- Day One Biopharmaceuticals, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
- May 24, 2024 (date) — Date of report
FAQ
What specific matter was submitted to a vote of Day One Biopharmaceuticals' security holders?
The filing does not specify the exact matter that was submitted to a vote of security holders.
What was the outcome of the shareholder vote on May 23, 2024?
The filing does not disclose the outcome or results of the shareholder vote.
When was the vote by Day One Biopharmaceuticals' security holders held?
The vote was held on May 23, 2024.
What is the principal executive office address for Day One Biopharmaceuticals, Inc.?
The principal executive offices are located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California 94005.
What is the IRS Employer Identification Number for Day One Biopharmaceuticals, Inc.?
The IRS Employer Identification Number is 83-2415215.
Filing Stats: 712 words · 3 min read · ~2 pages · Grade level 9 · Accepted 2024-05-24 16:02:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share DAWN Nasdaq Global Select
Filing Documents
- d832581d8k.htm (8-K) — 37KB
- 0001193125-24-147015.txt ( ) — 156KB
- dawn-20240523.xsd (EX-101.SCH) — 3KB
- dawn-20240523_lab.xml (EX-101.LAB) — 18KB
- dawn-20240523_pre.xml (EX-101.PRE) — 11KB
- d832581d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: May 24, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer